Filtros de búsqueda

Lista de obras de Filip Janků

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer

artículo científico publicado en 2016

A Tale of Two Histiocytic Disorders ⬇️

artículo científico publicado el 8 de enero de 2013

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors

artículo científico publicado en 2015

A framework for genomic biomarker actionability and its use in clinical decision making

artículo científico publicado en 2014

A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal

scientific article published on March 2013

A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma

artículo científico publicado en 2014

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

scientific article published on 20 June 2018

A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer

artículo científico publicado en 2006

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer

artículo científico publicado en 2014

A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies

artículo científico publicado en 2011

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

artículo científico publicado en 2014

A pilot study of temsirolimus and body composition

artículo científico publicado en 2013

A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease

ACTR-46. AG-120, A FIRST-IN-class MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION.

artículo científico publicado en 2017

Accessing Genetic Information with Liquid Biopsies

artículo científico

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

artículo científico publicado en 2015

Adjuvant interferon in high-risk melanoma: end of the era?

artículo científico publicado en 2009

Advances on the BRAF Front in Colorectal Cancer

artículo científico publicado en 2018

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic

artículo científico publicado en 2014

Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit

artículo científico publicado en 2014

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

artículo científico publicado en 2014

Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives

artículo científico publicado en 2014

Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer

artículo científico publicado en 2017

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors

artículo científico publicado en 2014

Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials

artículo científico publicado en 2016

Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients

artículo científico publicado en 2017

Autophagy as a target for anticancer therapy

artículo científico publicado en 2011

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

artículo científico

BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease

artículo científico publicado en 2014

BRAF mutation testing with a rapid, fully integrated molecular diagnostics system

artículo científico publicado en 2015

BRAF mutations in advanced cancers: clinical characteristics and outcomes

artículo científico publicado en 2011

Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit

artículo científico publicado en 2013

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation ⬇️

artículo científico publicado el 12 de febrero de 2013

Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway

artículo científico publicado en 2013

Bringing Blood-Based Molecular Testing to the Clinic

artículo científico publicado en 2016

Bringing target-matched PI3King from the bench to the clinic ⬇️

artículo científico publicado el 12 de junio de 2013

CD8+ T cell stimulation with pegylated recombinant human IL-10 in the patient with advanced solid tumors - a Phase I study.

artículo científico publicado en 2015

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.

artículo científico publicado en 2016

Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report

artículo científico publicado en 2015

Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer

scientific article published on 18 December 2019

Cell-free DNA as a novel marker in cancer therapy

artículo científico publicado en 2015

Challenges and perspective of drug repurposing strategies in early phase clinical trials

artículo científico publicado en 2015

Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience

artículo científico publicado en 2015

Characteristics and survival of patients with advanced cancer and p53 mutations

artículo científico publicado en 2014

Circulating tumor DNA-From bench to bedside

artículo científico

Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience

artículo científico publicado en 2014

Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas

artículo científico publicado en 2017

Clinical next generation sequencing to identify actionable aberrations in a phase I program

artículo científico publicado en 2015

Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer

scientific article published on 23 August 2018

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden

scientific article published on 14 August 2018

Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study

artículo científico publicado en 2004

Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease

artículo científico publicado en 2014

Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience

artículo científico publicado en 2016

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

article

Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

artículo científico publicado en 2018

Deciding site of biopsy at metastatic relapse: reply

artículo científico publicado en 2014

Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer

artículo científico publicado en 2017

Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers

artículo científico publicado en 2020

Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver

artículo científico publicado en 2015

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer

artículo científico publicado en 2014

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors

artículo científico publicado en 2014

Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies

artículo científico publicado en 2018

Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy

artículo científico publicado en 2016

Epithelial to mesenchymal transition is associated with rapamycin resistance

artículo científico publicado en 2015

Erdheim-Chester disease: characteristics and management

artículo científico

Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

artículo científico publicado en 2015

Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies

artículo científico publicado en 2015

Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies

artículo científico publicado en 2016

Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies

artículo científico publicado en 2013

Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials

artículo científico publicado en 2015

FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors

artículo científico publicado en 2014

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

artículo científico publicado en 2017

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

scientific article published on 10 December 2019

First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients

artículo científico publicado en 2017

Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm

artículo científico publicado en 2016

Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications

artículo científico publicado en 2013

HER2/neu-directed therapy for biliary tract cancer

artículo científico publicado en 2015

Highlights from the 7th central European lung cancer conference

artículo científico publicado en 2002

Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing

artículo científico publicado en 2014

Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act.

artículo científico publicado en 2017

Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-Refractory Advanced Solid Tumors

artículo científico publicado en 2020

Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses

artículo científico publicado en 2014

KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients

artículo científico publicado en 2005

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors

artículo científico publicado en 2012

Liquid Biopsies Using Plasma Exosomal Nucleic Acids

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers

artículo científico publicado en 2017

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

artículo científico publicado en 2014

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit

artículo científico publicado en 2014

MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors

artículo científico publicado en 2014

Metastatic Adenoid Cystic Carcinoma Mimicking Butterfly Glioblastoma: A Rare Presentation in the Splenium of the Corpus Callosum

artículo científico publicado en 2016

Molecular characterization of gallbladder cancer using somatic mutation profiling

artículo científico publicado en 2013

Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes

artículo científico publicado en 2020

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

artículo científico publicado en 2013

Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing

artículo científico publicado en 2015

Multiple gene aberrations and breast cancer: lessons from super-responders

artículo científico publicado en 2015

Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications

artículo científico publicado en 2014

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers

artículo científico

Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape

artículo científico publicado en 2017

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment ⬇️

artículo científico publicado el 1 de febrero de 2013

Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors

artículo científico publicado en 2014

Novel therapeutic targets in non-small cell lung cancer

artículo científico publicado en 2011

Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines

artículo científico publicado en 2015

Outcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancer

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials

artículo científico publicado en 2014

Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic

artículo científico publicado en 2011

Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program

artículo científico publicado en 2014

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience

artículo científico publicado en 2017

P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy

scientific article published on May 2013

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

artículo científico publicado en 2012

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials

artículo científico publicado en 2012

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers

artículo científico publicado en 2011

PIK3CA mutations in advanced cancers: characteristics and outcomes

artículo científico publicado en 2012

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

artículo científico publicado en 2011

Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment

artículo científico publicado en 2010

Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses

artículo científico publicado en 2014

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative

artículo científico publicado en 2012

Personalized medicine in advanced non-small-cell lung cancer: reality or wishful thinking?

artículo científico publicado en 2008

Phase 1 dose-escalation study of anti CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers

artículo científico publicado en 2017

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies

scientific article published on 01 November 2018

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer

artículo científico publicado en 2016

Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer

artículo científico publicado en 2014

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

artículo científico publicado en 2017

Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer

artículo científico publicado en 2016

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer

artículo científico publicado en 2013

Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer

artículo científico publicado en 2013

Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy

artículo científico publicado en 2015

Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers

artículo científico publicado en 2016

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

artículo científico publicado en 2016

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

artículo científico publicado en 2020

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

artículo científico publicado en 2014

Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors

artículo científico publicado en 2020

Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer

artículo científico publicado en 2017

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors

artículo científico publicado en 2017

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation

artículo científico publicado en 2016

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

artículo científico publicado en 2015

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

artículo científico publicado en 2018

Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients

artículo científico publicado en 2017

Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit

artículo científico publicado en 2016

Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.

artículo científico publicado en 2018

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

artículo científico publicado en 2016

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic

Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar Hepatocellular Carcinoma ⬇️

artículo científico publicado el 19 de septiembre de 2013

Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders

artículo científico publicado en 2014

Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors

artículo científico publicado en 2017

Response of histiocytoses to imatinib mesylate: fire to ashes

artículo científico publicado en 2010

Retreatment after secondary resistance or mixed response: a pilot study

artículo científico publicado en 2013

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages

scientific article published on 10 March 2016

Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population

artículo científico publicado en 2013

Ridaforolimus in Advanced Sarcomas: A Leap Forward or Missed Opportunity? ⬇️

artículo científico publicado el 30 de enero de 2012

STAT3 inhibitors: finding a home in lymphoma and leukemia

artículo científico publicado en 2014

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

artículo científico publicado en 2020

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

artículo científico publicado en 2017

Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials

artículo científico publicado en 2016

Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).

artículo científico publicado en 2010

Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience

artículo científico publicado en 2016

Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma

artículo científico publicado en 2005

Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic

artículo científico publicado en 2014

TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics

artículo científico publicado en 2016

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations

artículo científico publicado en 2013

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience

artículo científico publicado en 2014

Targeted therapies for advanced Ewing sarcoma family of tumors

artículo científico publicado en 2015

Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome

artículo científico

Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome

artículo científico

Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome.

artículo científico publicado en 2014

Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

scientific article published on 15 June 2010

Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials

artículo científico publicado en 2013

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab

artículo científico publicado en 2014

Targeting isocitrate dehydrogenase (IDH) in cancer

artículo científico publicado en 2016

Targeting the PI3K pathway in cancer: are we making headway?

artículo científico publicado en 2018

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab

artículo científico publicado en 2016

Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?

artículo científico publicado en 2015

The mu opioid receptor: A new target for cancer therapy?

artículo científico

Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses

artículo científico publicado en 2013

Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents

artículo científico publicado en 2014

Tumor heterogeneity in the clinic: is it a real problem?

artículo científico publicado en 2014

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms

artículo científico publicado en 2014

Unusual presentation of gastrointestinal stromal tumor with early cerebral involvement ⬇️

artículo científico publicado el 30 de septiembre de 2010

Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center

artículo científico publicado en 2011

Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer

artículo científico publicado en 2015

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda